

REMARKS

Examiner Thurman Page is thanked for having graciously held an interview with Dr. Tim Creagan and the undersigned on August 1, 2005 for his suggestions with regard to the 131 declaration from Joseph Mertz. As suggested by Examiner Page, Applicants hereby include a new 131 declaration from all three inventors stating their individual contributions to each pending claim.

Claims 124-143 were pending in the present application. Claims 124, 125 and 134-142 are amended to replace the phrase "form F azithromycin" with the phrase "azithromycin monohydrate hemi-ethanol solvate." Claim 143 is canceled without prejudice and claim 144 is introduced. Support for the amendments to claims 124, 125 and 134-142 can be found, *inter alia*, in lines 14-15 on page 2 and lines 13-21 on page 5 of the original specification. Support for new claim 144 can be found, *inter alia*, on page 15, lines 3-5 and lines 10-11 of the original specification. Therefore, the present Supplemental Amendment is fully supported by the original specification and does not raise any issue of new matter. Accordingly, entry of the present Supplemental Amendment is respectfully requested. Upon entry of the present Supplemental Amendment, claims 124-142 and 144 will be under examination.

CONCLUSION

In view of the claim amendments and remarks, further and favorable consideration of claims 124-142 and 144 are respectfully requested. The Examiner is invited to contact the undersigned if he wishes to discuss details of the present Supplemental Amendment.

Respectfully submitted,

Date: Aug. 11, 2005

By: Lance Y. Liu

Lance Y. Liu
Attorney for Applicants
Reg. No. 45,379

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-1652